Omega-3 supplementation confers no benefit for vascular events in diabetics
Supplementation with n−3 or omega-3 fatty acids does not help prevent serious vascular events in diabetic patients without evidence of cardiovascular disease at baseline, according to a study.
A total of 15,480 patients (mean age 63.3 years; 62.6 percent male) with diabetes but without atherosclerotic cardiovascular disease were randomized to receive 1-g capsules containing either omega-3 fatty acids (n=7,740) or matching placebo (olive oil; n=7,740) daily.
The incidence of a primary outcome of a first serious vascular event (ie, nonfatal myocardial infarction or stroke, transient ischaemic attack, or vascular death, excluding confirmed intracranial haemorrhage) between the two groups was similar, occurring in 689 patients (8.9 percent) in the fatty acid group and in 712 (9.2 percent) in the placebo group (rate ratio, 0.97; 95 percent CI, 0.87–1.08; p=0.55) during a mean follow-up of 7.4 years.
Likewise, the secondary outcome of a composite of serious vascular event or revascularization was comparable between the fatty acid and placebo groups (882 [11.4 percent] vs 887 [11.5 percent], respectively; rate ratio, 1.00; 0.91–1.09).
No significant between-group difference was observed in death from any cause, occurring in 752 patients (9.7 percent) in the fatty acid group and in 788 (10.2 percent) in the placebo group (rate ratio, 0.95; 0.86–1.05), as well as in the rates of nonfatal serious adverse events.
The present data, together with results of earlier randomized trials involving patients with and those without diabetes, are in opposition to the current recommendations for routine dietary supplementation with n−3 fatty acids to prevent vascular events, researchers said.